STOCK TITAN

Foghorn Therapeutics Inc. - FHTX STOCK NEWS

Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.

Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical pioneer developing precision medicines targeting chromatin regulation in oncology. This news hub provides investors and industry professionals with essential updates on the company's therapeutic pipeline, strategic collaborations, and clinical milestones.

Access timely reports on FHTX's innovative programs including FHD-286 (hematologic cancers), FHD-609 (synovial sarcoma), and FHD-909 (non-small cell lung cancer). Stay informed about regulatory developments, partnership announcements, and scientific presentations related to their Gene Traffic Control platform.

Our curated news collection serves as a comprehensive resource for tracking progress across preclinical studies, clinical trials, and business operations. Bookmark this centralized source for verified updates on Foghorn's novel protein degraders and chromatin-targeting therapies.

Rhea-AI Summary
Stoke Therapeutics appoints Ian Smith to its Board of Directors, bringing significant experience in the development of medicines for rare genetic diseases. Smith's expertise and track record in the biotech industry will be valuable as Stoke advances STK-001 for Dravet syndrome. This represents a unique opportunity to develop disease-modifying medicines for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
-
Rhea-AI Summary
Foghorn Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary
Foghorn Therapeutics announces dosing of first patient in Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.25%
Tags
Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Headquarters in New York City. The session, featuring President and CEO Adrian Gottschalk, will take place at 1:30 p.m. ET. Foghorn is focused on developing innovative medicines that address abnormal gene expression, particularly in oncology, through its Gene Traffic Control platform. A webcast of the panel discussion will be available on Foghorn's website for 30 days following the event. For more details, visit www.foghorntx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
conferences
Foghorn Therapeutics Inc.

Nasdaq:FHTX

FHTX Rankings

FHTX Stock Data

211.33M
45.00M
18.98%
72.61%
1.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE